Titre : Uridine diphosphate

Uridine diphosphate : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin II
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate : Questions médicales les plus fréquentes", "headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-22", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Uridine diphosphate" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Nucléotides uridyliques", "url": "https://questionsmedicales.fr/mesh/D014500", "about": { "@type": "MedicalCondition", "name": "Nucléotides uridyliques", "code": { "@type": "MedicalCode", "code": "D014500", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate ose", "alternateName": "Uridine Diphosphate Sugars", "url": "https://questionsmedicales.fr/mesh/D014539", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate ose", "code": { "@type": "MedicalCode", "code": "D014539", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylgalactosamine", "alternateName": "Uridine Diphosphate N-Acetylgalactosamine", "url": "https://questionsmedicales.fr/mesh/D014536", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylgalactosamine", "code": { "@type": "MedicalCode", "code": "D014536", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.100" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylglucosamine", "alternateName": "Uridine Diphosphate N-Acetylglucosamine", "url": "https://questionsmedicales.fr/mesh/D014537", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylglucosamine", "code": { "@type": "MedicalCode", "code": "D014537", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.120" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate N-acétylmuramique", "alternateName": "Uridine Diphosphate N-Acetylmuramic Acid", "url": "https://questionsmedicales.fr/mesh/D014538", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate N-acétylmuramique", "code": { "@type": "MedicalCode", "code": "D014538", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.150" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate galactose", "alternateName": "Uridine Diphosphate Galactose", "url": "https://questionsmedicales.fr/mesh/D014531", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate galactose", "code": { "@type": "MedicalCode", "code": "D014531", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.300" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate glucose", "alternateName": "Uridine Diphosphate Glucose", "url": "https://questionsmedicales.fr/mesh/D014532", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate glucose", "code": { "@type": "MedicalCode", "code": "D014532", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.350" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate glucuronique", "alternateName": "Uridine Diphosphate Glucuronic Acid", "url": "https://questionsmedicales.fr/mesh/D014535", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate glucuronique", "code": { "@type": "MedicalCode", "code": "D014535", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.375" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate xylose", "alternateName": "Uridine Diphosphate Xylose", "url": "https://questionsmedicales.fr/mesh/D014540", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate xylose", "code": { "@type": "MedicalCode", "code": "D014540", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.800" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate", "alternateName": "Uridine Diphosphate", "code": { "@type": "MedicalCode", "code": "D014530", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takayuki Matsumoto", "url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp." } }, { "@type": "Person", "name": "Kumiko Taguchi", "url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan." } }, { "@type": "Person", "name": "Tsuneo Kobayashi", "url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp." } }, { "@type": "Person", "name": "Rafal Jonczyk", "url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } }, { "@type": "Person", "name": "Thomas Hoffmann", "url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review.", "datePublished": "2023-02-01", "url": "https://questionsmedicales.fr/article/36753927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajem.2023.01.050" } }, { "@type": "ScholarlyArticle", "name": "Unraveling allostery within the angiotensin II type 1 receptor for Gα", "datePublished": "2023-08-08", "url": "https://questionsmedicales.fr/article/37552769", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1126/scisignal.adf2173" } }, { "@type": "ScholarlyArticle", "name": "Circulating angiotensin II type I receptor - autoantibodies in diabetic pregnancies.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36495655", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jri.2022.103777" } }, { "@type": "ScholarlyArticle", "name": "Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipients.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35771088", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ctr.14754" } }, { "@type": "ScholarlyArticle", "name": "RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic targeting.", "datePublished": "2023-11-03", "url": "https://questionsmedicales.fr/article/37922976", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bcp.2023.115904" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides nucléiques, nucléotides et nucléosides", "item": "https://questionsmedicales.fr/mesh/D009706" }, { "@type": "ListItem", "position": 3, "name": "Nucléotides", "item": "https://questionsmedicales.fr/mesh/D009711" }, { "@type": "ListItem", "position": 4, "name": "Ribonucléotides", "item": "https://questionsmedicales.fr/mesh/D012265" }, { "@type": "ListItem", "position": 5, "name": "Nucléotides uridyliques", "item": "https://questionsmedicales.fr/mesh/D014500" }, { "@type": "ListItem", "position": 6, "name": "Uridine diphosphate", "item": "https://questionsmedicales.fr/mesh/D014530" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Uridine diphosphate - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Uridine diphosphate", "description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Uridine diphosphate", "description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Uridine diphosphate", "description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Uridine diphosphate", "description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Uridine diphosphate", "description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Uridine diphosphate", "description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en UDP ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'UDP ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP." } }, { "@type": "Question", "name": "L'UDP peut-il être mesuré dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème d'UDP ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une carence en UDP ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs." } }, { "@type": "Question", "name": "L'UDP affecte-t-il le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs." } }, { "@type": "Question", "name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré." } }, { "@type": "Question", "name": "L'UDP influence-t-il l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés à l'UDP ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes." } }, { "@type": "Question", "name": "Comment prévenir une carence en UDP ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence." } }, { "@type": "Question", "name": "Les suppléments sont-ils nécessaires pour l'UDP ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque pour l'UDP ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles l'UDP ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP." } }, { "@type": "Question", "name": "Des conseils nutritionnels existent-ils pour l'UDP ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté." } }, { "@type": "Question", "name": "Comment traiter une carence en UDP ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à l'UDP ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour l'UDP ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études." } }, { "@type": "Question", "name": "Les changements alimentaires sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des traitements spécifiques existent-ils pour l'UDP ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une carence en UDP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées." } }, { "@type": "Question", "name": "L'UDP peut-il affecter le développement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants." } }, { "@type": "Question", "name": "Des maladies chroniques sont-elles liées à l'UDP ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP." } }, { "@type": "Question", "name": "L'UDP est-il impliqué dans des maladies héréditaires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'UDP ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'UDP ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence." } }, { "@type": "Question", "name": "Le stress peut-il affecter l'UDP ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences." } }, { "@type": "Question", "name": "Les maladies génétiques influencent-elles l'UDP ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP." } }, { "@type": "Question", "name": "Les habitudes alimentaires jouent-elles un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP." } } ] } ] }

Sources (10000 au total)

Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review.

Cardiogenic shock (CS) is associated with high morbidity and mortality. In recent times, there is increasing interest in the role of angiotensin II in CS. We sought to systematically review the curren... PubMed, EMBASE, Medline, Web of Science, PubMed Central, and CINAHL databases were systematically searched for studies that evaluated the efficacy of angiotensin II in patients with CS during 01/01/20... Of the total 2,402 search results, 15 studies comprising 195 patients were included of which 156 (80%) received angiotensin II. Eleven patients (84.6%) in case reports and case series with reported MA... In this first systematic review of angiotensin II in CS, we note the early clinical experience. Angiotensin II was associated with improvements in MAP, decrease in vasopressor requirements, and minima...

Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipients.

Due to the mechanisms of action of conventional catecholamine vasopressors, there is increased risk of renal allograft injury and adverse events in transplant recipients with fluid-refractory distribu... This was a single-center, single-arm, open-label, phase 4 study conducted as a 1-year pilot of 20 adult renal transplant recipients receiving ATII as their first continuous infusion vasopressor in the... Most cases involved deceased donors (70%), with a corresponding mean (SD) cold ischemia time of 14.7 (8.6) h. Over a surgery duration of 5.3 (1.2) h, subjects received 3.2 (2.0) L of total volume resu... Based on the observations of this pilot study, ATII is a safe and effective vasopressor option for renal transplant recipients requiring perioperative hypotension reversal....

Relationship between Angiotensin II, Vascular Endothelial Growth Factor, and Arteriosclerosis Obliterans.

To investigate the relationship between angiotensin II (Ang II), vascular endothelial growth factor (VEGF), and arteriosclerosis obliterans (ASO).... 60 ASO patients diagnosed and treated from October 2019 to December 2021 were selected for the observation group while 30 healthy physical examiners were for the control group. The general information... (1) The proportion of males with a history of smoking, diabetes, and hypertension was higher (... Ang II and VEGF were correlated with the occurrence and development of ASO. The AUC analysis demonstrates that Ang II and VEGF were highly discriminative of ASO....

The role of donor hypertension and angiotensin II in the occurrence of early pancreas allograft thrombosis.

About 10-20% of pancreas allografts are still lost in the early postoperative period despite the identification of numerous detrimental risk factors that correlate with graft thrombosis.... We conducted a multicenter study including 899 pancreas transplant recipients between 2000 and 2018. Early pancreas failure due to complete thrombosis, long-term pancreas, kidney and patient survivals... Pancreas from donors with history of hypertension (6.7%), as well as with high body mass index (BMI), were independently associated with an increased risk of pancreas failure within the first 30 post-... Donor hypertension was a significant and independent risk factor of pancreas failure. The well-known pathogenic role of renin-angiotensin-aldosterone system seems to be involved in the genesis of this...

Cyr61 Mediates Angiotensin II-Induced Podocyte Apoptosis via the Upregulation of TXNIP.

It is well documented that angiotensin II (Ang II) elevation promotes apoptosis of podocytes... Podocytes were treated with Ang II (10... The expression of Cyr61, TXNIP, Cyt-c, and Bax in podocytes treated with Ang II were upregulated, but the expression and apoptotic rates of Bcl-2 in podocytes were inhibited. The level of the above fa... The results of the study extrapolate that Cyr61 plays a dominant role in Ang II-induced podocyte apoptosis. Additionally, Cyr61 may mediate the Ang II-induced podocyte apoptosis by promoting the expre...